Successful RF power testing of the first CCL unit

RNS Number : 5723N

Advanced Oncotherapy PLC

19 May 2015

 

19 May 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Successful RF Power testing of the first CCL unit

Completion of key milestone in the development of the LIGHT System

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Radio Frequency ("RF") Power tests of the first Coupled Cavity Linac ("CCL") unit have been successfully completed at the Company's testing facility at CERN in line with expectations.

The RF Power units, created by ScandiNova Systems AB ("ScandiNova"), generate the high-power needed to accelerate protons to speeds whereby they can effectively target cancer cells. The RF Power units include the modulator, for the early delivery of which, our partner ScandiNova accepted part payment in shares as announced on 2 April 2015.

This announcement follows the successful completion in January of the LIGHT system's first CCL unit, an accelerating structure that consists of a series of cells that accelerate protons from energies of 37.5 Mega-electron Volts (MeV) to the full 230MeV required to treat all radiosensitive tumours.

On 1 May 2015 the Company announced a successful £20m fundraise net of expenses to continue the development of its LIGHT system, with the first unit expected to be installed in Harley Street, London, by the end of 2016 and first patient treatments expected in 2017.

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: "In November last year we gave investors a clear pathway towards the delivery of our first LIGHT system and I am delighted that we continue to deliver to this timetable on time and to budget, with the successful RF Power testing of the first CCL unit. Our recent funding has provided the Company with the financial security that we need to deliver our ground-breaking proton therapy technology which we expect will be treating patients in the heart of London in 2017."

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCEAESPFDASEAF